title: [Cardiometabolic and cardiorenal syndromes interactions in Algerian diabetic-hypertensive patient: interest of predictive multi-biomarkers strategy to renal dysfunction].
abstract: The coexistence of essential hypertension (EH) in type 2 diabetic (T2D) patients greatly enhances chronic kidney disease.
  
  
  OBJECTIVE
  To assess the acute renal dysfunction in two cohorts of diabetic-hypertensive subjects. The inaugural pathology for each group is either T2D or EH.
  
  
  METHODS
  The study was undertaken on 506 subjects who were divided in 5 groups according to age and sex: diabetic, hypertensive, diabetic- hypertensive (DH and HD) and healthy groups. Patients were phenotyped regarding their cardiometabolic syndrome (CMS) profile using the NCEP/ATPIII criteria and cardiorenal syndrome (CRS) according to the International kidney foundation. Hypertension was defined as systolic (SBP) and diastolic (DBP) blood pressure ≥ 140/90 mmHg, respectively. Insulin resistance (IR) was assessed by Homa-IR model. Glomerular filtration rate (GFR) by creatinine clearance. CMS and CRS parameters were determined on Cobas®. The SBP and DBP measurements by electronic blood pressure using Omron 705 CP® type.
  
  
  RESULTS
  IR was found in all diabetics and hypertensive patients. Dyslipidemia are correlated to % body fat mass accretion in all groups. In DH group, the renal disorder is confirmed by decreased GFR (30%) and increased microalbuminuria (> 30 mg/24h); associated with increased NT-pro BNP and plasma aldosterone depletion.
  
  
  CONCLUSIONS
  Several biomarkers are necessary to detection kidney disease and renal failure prevention in diabetic patients to hypertensive state. The renal dysfunction was significantly related to T2D-EH disease.
authors.affiliation: Université des sciences et de la technologie Houari Boumediene, Faculté des sciences biologiques, Laboratoire de biologie et physiologie des organismes, Équipe de bioénergétique et métabolisme intermédiaire, Alger, Algérie, École nationale supérieure de Kouba, Alger, Algérie.
authors.forename: Houda
authors.initials: H
authors.lastname: Zoubiri
authors.affiliation: Laboratoire de biochimie, CHU-Hôpital Mohamed Seghir Nekache, Alger, Algérie.
authors.forename: Ghouti
authors.initials: G
authors.lastname: Kacimi
authors.affiliation: Service de médecine nucléaire, CHU-Hôpital Mohamed Seghir Nekache, Alger, Algérie.
authors.forename: El Mahdi
authors.initials: el M
authors.lastname: Haffaf
authors.affiliation: Service de diabétologie, Hôpital Mohamed Seghir Nekache, Alger, Algérie.
authors.forename: Brahim
authors.initials: B
authors.lastname: Oudjit
authors.affiliation: Service de cardiologie, CHU-Hôpital Mohamed Seghir Nekache, Alger, Algérie.
authors.forename: Naima
authors.initials: N
authors.lastname: Adjroud
authors.affiliation: Université des sciences et de la technologie Houari Boumediene, Faculté des sciences biologiques, Laboratoire de biologie et physiologie des organismes, Équipe de bioénergétique et métabolisme intermédiaire, Alger, Algérie.
authors.forename: Elhadj-Ahmed
authors.initials: EA
authors.lastname: Koceir
mesh_terms: D000462:Algeria; D015415:Biomarkers / Q000097:blood; D059347:Cardio-Renal Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications*; D003928:Diabetic Nephropathies / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D000075222:Essential Hypertension; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology*; D008137:Longitudinal Studies; D008297:Male; D008659:Metabolic Diseases / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D008875:Middle Aged; D011237:Predictive Value of Tests
chemical_list: D015415:Biomarkers
keywords: cardiometabolic syndrome; cardiorenal syndrome; essential hypertension; insulinresistance; renal dysfunction; reno-cardiac and metabolic biomarkers; type 2 diabetes